Overview

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the recommended dose of combination of dovitinib and imatinib in phase I study.
Phase:
Phase 1
Details
Lead Sponsor:
Asan Medical Center
Treatments:
Imatinib Mesylate